Improve safety and wider range of clinical use - RespIn 11 does not cause important negative changes to various patient physiological parameters, ie making BP, HR rise as do existing HFCWO/Chest Compression devices. In fact, Pre-Clinical Trial Safety Study data shows both those figures gradually reducing during therapy sessions of 15 or 20 minutes.

Safety and test subject feedback has been unanimous in indicating their preference for the RespIn 11 `focus pulse` system. The RespIn 11 has a very low level of clinically measurable impact on the physiological state of the patient during therapy sessions with no negative measured effects on heart rate, blood pressure, ECG, etc. - unlike the existing HFCWO/Chest Compression devices which cause patients significant physiological changes and distress. This means not only a wider range of potential patients in clinical situations, but also a much higher regular usage rate for Home Care patients because of its pleasant massage effect leading to better long term results with accompanying improvements in quality of life and decreased frequency of acute acerbations requiring hospital treatment.

Clinical Areas and applications where RespInnovation’s `focused pulse` technology could be used more effectively than existing Chest Compression devices:

Neuro-muscular disease patients, MS, ALS, etc. / The long term bed care patient. / The elderly, both as a preventative therapy to prevent lung infections and also a secretion clearance system once they have an infection. / Intensive care and post-operative patients.

RespInnovation SAS Downloads

RespIn 11 Info Pack

Contact supplier